AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36463498 — intervention group
Group type: EXPERIMENTAL
Intervention: Live music during haemodialysis (30 minutes once a week for 6 weeks)
Number of subjects: 24
Study 36463498 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 24
Study 36463498 — intervention group
Group type: EXPERIMENTAL
Intervention: Live music during haemodialysis
Number of subjects: 24
Study 34295831 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive probiotic group (Lacticaseibacillus rhamnosus GR‐1 and Limosilactobacillus reuteri RC‐14 orally for 30 days)
Number of subjects: 126
Study 34295831 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole group (metronidazole vaginal suppositories for 7 days)
Number of subjects: 126
Study 34295831 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive probiotic group
Number of subjects: 126
Study 34295831 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole group
Number of subjects: 126
Study 34655389 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 67
Study 34655389 — intervention group
Group type: COMPARATOR
Intervention: Support/Education (active control intervention)
Number of subjects: 67
Study 32273381 — intervention group
Group type: COMPARATOR
Intervention: Standard USAF SAPP
Number of subjects: 51
Study 32273381 — intervention group
Group type: EXPERIMENTAL
Intervention: USAF SAPP with MI enhancement
Number of subjects: 51
Study 32273381 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Standard USAF SAPP and USAF SAPP with MI enhancement)
Number of subjects: 51
Study 36050448 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (T)
Number of subjects: 2821
Study 36050448 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (T) + Lapatinib (L)
Number of subjects: 2821
Study 36050448 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib (L)
Number of subjects: 2821
Study 33160896 — intervention group
Group type: EXPERIMENTAL
Intervention: Mummy Buddy Program (peer support intervention)
Number of subjects: 47
Study 35176755 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (Arm A, TAMOX/VOR)
Number of subjects: 31
Study 35176755 — intervention group
Group type: COMPARATOR
Intervention: Vorinostat (Arm B, VOR)
Number of subjects: 31
Study 35176755 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen and Vorinostat
Number of subjects: 31
Study 34487958 — intervention group
Group type: EXPERIMENTAL
Intervention: Extremely randomized neural networks
Number of subjects: 0
Study 34487958 — intervention group
Group type: COMPARATOR
Intervention: State-of-the-art methods (MC dropout and bootstrap procedures)
Number of subjects: 0
Study 35238305 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg/day for 7 days)
Number of subjects: 497
Study 35238305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 497
Study 32493098 — intervention group
Group type: EXPERIMENTAL
Intervention: QFT-Plus test for LTBI
Number of subjects: 3024
Study 32493098 — intervention group
Group type: EXPERIMENTAL
Intervention: Older than 50 years
Number of subjects: 3024
Study 32493098 — intervention group
Group type: EXPERIMENTAL
Intervention: From the Philippines
Number of subjects: 3024
Study 32493098 — intervention group
Group type: EXPERIMENTAL
Intervention: From the Indian subcontinent
Number of subjects: 3024
Study 32493098 — intervention group
Group type: EXPERIMENTAL
Intervention: Working as a nurse
Number of subjects: 3024
Study 32493098 — intervention group
Group type: EXPERIMENTAL
Intervention: Allied health profession
Number of subjects: 3024
Study 32493098 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiology technician
Number of subjects: 3024
Study 32493098 — intervention group
Group type: EXPERIMENTAL
Intervention: Working in the emergency room
Number of subjects: 3024
Study 32493098 — intervention group
Group type: EXPERIMENTAL
Intervention: Working in the intensive care unit
Number of subjects: 3024
Study 32493098 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group older than 50 years
Number of subjects: 3024
Study 32493098 — intervention group
Group type: EXPERIMENTAL
Intervention: Known TB exposure
Number of subjects: 3024
Study 32493098 — intervention group
Group type: EXPERIMENTAL
Intervention: Not receiving BCG at birth
Number of subjects: 3024
Study 32750703 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy (PT)
Number of subjects: 84
Study 32750703 — intervention group
Group type: COMPARATOR
Intervention: X-ray therapy (XRT)
Number of subjects: 84
Study 33044178 — intervention group
Group type: EXPERIMENTAL
Intervention: HP‐EH‐EVOO (50 mL/day)
Number of subjects: 0
Study 33044178 — intervention group
Group type: EXPERIMENTAL
Intervention: MP‐EVOO (50 mL/day)
Number of subjects: 0
Study 33044178 — intervention group
Group type: COMPARATOR
Intervention: MeDi
Number of subjects: 0
Study 33044178 — intervention group
Group type: EXPERIMENTAL
Intervention: HP‐EH‐EVOO and MP‐EVOO
Number of subjects: 0
Study 35341692 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized integration titanium mesh (CITM)
Number of subjects: 20
Study 35341692 — intervention group
Group type: COMPARATOR
Intervention: Traditional titanium plates
Number of subjects: 20
Study 32671559 — intervention group
Group type: EXPERIMENTAL
Intervention: MAF group
Number of subjects: 34
Study 32671559 — intervention group
Group type: EXPERIMENTAL
Intervention: Activator group
Number of subjects: 34
Study 32671559 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 34
Study 35322709 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (20 Hz, delivered over the left dorsolateral prefrontal cortex, 100% rest motor threshold)
Number of subjects: 40
Study 35322709 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (same protocol as active but without magnetic stimulation)
Number of subjects: 40
Study 35322709 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 40
Study 35389559 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthesis buccal emergence profile design based on the buccal mucosal W/H ratio (Test Group)
Number of subjects: 21
Study 35389559 — intervention group
Group type: COMPARATOR
Intervention: Original emergence profile of the healing abutment (Control Group)
Number of subjects: 21
Study 34051880 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus Bevacizumab
Number of subjects: 501
Study 34051880 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 501
Study 33988836 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-vessel coronary artery disease (MV-CAD)
Number of subjects: 507
Study 33988836 — intervention group
Group type: COMPARATOR
Intervention: Single-vessel coronary artery disease (SV-CAD)
Number of subjects: 507
Study 33988836 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-vessel disease
Number of subjects: 507
Study 33988836 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-vessel disease
Number of subjects: 507
Study 34491014 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) only
Number of subjects: 42
Study 34491014 — intervention group
Group type: EXPERIMENTAL
Intervention: AMX + MET after SRP
Number of subjects: 42
Study 34491014 — intervention group
Group type: EXPERIMENTAL
Intervention: AMX + MET during SRP
Number of subjects: 42
Study 32557991 — intervention group
Group type: EXPERIMENTAL
Intervention: Low AM (200 mg/kg BW)
Number of subjects: 16
Study 32557991 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle AM (400 mg/kg BW)
Number of subjects: 16
Study 32557991 — intervention group
Group type: EXPERIMENTAL
Intervention: High AM (800 mg/kg BW)
Number of subjects: 16
Study 32557991 — intervention group
Group type: COMPARATOR
Intervention: CON (0 mg/kg BW)
Number of subjects: 16
Study 35869267 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral selinexor 60 mg twice weekly (days 1–24) with standard chemotherapy (3 + 7)
Number of subjects: 102
Study 35869267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine 1000 mg/m2 twice daily, days 1–6 with selinexor
Number of subjects: 102
Study 35869267 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (3 + 7) without selinexor
Number of subjects: 102
Study 33952438 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed incision negative pressure wound therapy (NPWT)
Number of subjects: 2035
Study 33952438 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 2035
Study 34260849 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab plus Etesevimab (2800 mg each, administered together)
Number of subjects: 1035
Study 34260849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1035
Study 34260849 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab plus Etesevimab
Number of subjects: 1035
Study 33308472 — intervention group
Group type: EXPERIMENTAL
Intervention: Video laryngoscopy
Number of subjects: 564
Study 33308472 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 564
Study 32752924 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary assisted dying training (9 modules including an assessment module)
Number of subjects: 0
Study 32752924 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment module (30 questions with a pass mark of 90%)
Number of subjects: 0
Study 32121016 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee-cascara yogurt with 13% inulin (Y13)
Number of subjects: 45
Study 32121016 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee-cascara yogurt with 3% inulin (Y3)
Number of subjects: 45
Study 32121016 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee-cascara yogurt with 7% inulin (Y7)
Number of subjects: 45
Study 32121016 — intervention group
Group type: COMPARATOR
Intervention: Coffee-cascara yogurt without inulin (Y0)
Number of subjects: 45
Study 32418922 — intervention group
Group type: EXPERIMENTAL
Intervention: With-sensor group
Number of subjects: 124
Study 32418922 — intervention group
Group type: COMPARATOR
Intervention: Without-sensor group
Number of subjects: 124
Study 34245243 — intervention group
Group type: EXPERIMENTAL
Intervention: ccIIV4
Number of subjects: 727
Study 34245243 — intervention group
Group type: EXPERIMENTAL
Intervention: RIV4
Number of subjects: 727
Study 32168484 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery (direct or combined direct/indirect) in SS1+2 subgroup
Number of subjects: 79
Study 32168484 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical cohort SS0 group
Number of subjects: 79
Study 32168484 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical cohort SS1+2 group
Number of subjects: 79
Study 32168484 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical cohort overall
Number of subjects: 79
Study 32168484 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery in SS0 group
Number of subjects: 79
Study 616403436 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (120 mg) with carboplatin/paclitaxel
Number of subjects: 158
Study 616403436 — intervention group
Group type: COMPARATOR
Intervention: Placebo with carboplatin/paclitaxel
Number of subjects: 158
Study 34877238 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 50
Study 34877238 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 50
Study 34877238 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endurance + resistance training
Number of subjects: 50
Study 34877238 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 32997219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) treatment
Number of subjects: 0
Study 32986265 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (6 months of intradialytic exercise)
Number of subjects: 15
Study 32986265 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise therapy)
Number of subjects: 15
Study 36336274 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress group
Number of subjects: 52
Study 36336274 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 34602438 — intervention group
Group type: EXPERIMENTAL
Intervention: Femitex‐SP4 (500 mg powdered herbs in capsule form, twice daily)
Number of subjects: 150
Study 34090550 — intervention group
Group type: EXPERIMENTAL
Intervention: PFMT+CTM
Number of subjects: 34
Study 34090550 — intervention group
Group type: COMPARATOR
Intervention: PFMT
Number of subjects: 34
Study 32690739 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal surfactant (120 mg vial for <26 weeks GA; 240 mg vial for 26-28 +6 weeks GA) in addition to CPAP
Number of subjects: 0
Study 32690739 — intervention group
Group type: COMPARATOR
Intervention: CPAP alone
Number of subjects: 0
Study 32690739 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal surfactant
Number of subjects: 0
Study 36232163 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 43
Study 34185587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal 1.0 mg risuteganib
Number of subjects: 45
Study 34185587 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 45
Study 35458199 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium longum and Lactobacillus reuteri)
Number of subjects: 60
Study 35458199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34152273 — intervention group
Group type: EXPERIMENTAL
Intervention: CSLR model with engineered features
Number of subjects: 35
Study 34152273 — intervention group
Group type: COMPARATOR
Intervention: CSLR model with basic features
Number of subjects: 35
Study 34436618 — intervention group
Group type: EXPERIMENTAL
Intervention: Norms module
Number of subjects: 3244
Study 34436618 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancies module
Number of subjects: 3244
Study 34436618 — intervention group
Group type: EXPERIMENTAL
Intervention: Other modules
Number of subjects: 3244
Study 34062418 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 3 × 500 mg (group A)
Number of subjects: 25
Study 34062418 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 3 × 1000 mg (group B)
Number of subjects: 25
Study 34062418 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 25
Study 32022282 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandoz biosimilar pegfilgrastim
Number of subjects: 0
Study 32022282 — intervention group
Group type: COMPARATOR
Intervention: US-approved reference biologics
Number of subjects: 0
Study 32022282 — intervention group
Group type: COMPARATOR
Intervention: EU-approved reference biologics
Number of subjects: 0
Study 35124703 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant capecitabine-containing chemotherapy (TX + CEX: capecitabine-docetaxel, followed by cyclophosphamide-epirubicin-capecitabine)
Number of subjects: 202
Study 35124703 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (T + CEF: docetaxel, followed by cyclophosphamide-epirubicin-fluorouracil)
Number of subjects: 202
Study 33016132 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted training (12 sessions at the ARMEO®-Spring)
Number of subjects: 48
Study 33016132 — intervention group
Group type: COMPARATOR
Intervention: Usual occupational and physiotherapy (control group)
Number of subjects: 48
Study 32580984 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week Mindfulness-based stress reduction (MBSR) program
Number of subjects: 40
Study 32580984 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 40
Study 33813084 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin (30 μg/kg for 7 days)
Number of subjects: 60
Study 33813084 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin (56 μg/kg for 7 days)
Number of subjects: 60
Study 33813084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32044758 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-featured study app
Number of subjects: 328
Study 32044758 — intervention group
Group type: COMPARATOR
Intervention: Control group with fewer app features
Number of subjects: 328
Study 36425882 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-extremity joint manipulation
Number of subjects: 8
Study 35752785 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI assessment of axillary lymph nodes at baseline, interim, and preoperative time points
Number of subjects: 33
Study 35752785 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI assessment of the most suspicious LN
Number of subjects: 33
Study 35752785 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI assessment of posttreatment nodal status
Number of subjects: 33
Study 35752785 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI diagnosis of ypN0 cases
Number of subjects: 33
Study 35752785 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging (DWI) assessment
Number of subjects: 33
Study 34422246 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast inhalation and slow exhalation (A) group
Number of subjects: 90
Study 34422246 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal breathing (B) group
Number of subjects: 90
Study 34422246 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 90
Study 36067241 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application for symptom management
Number of subjects: 40
Study 36067241 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 40
Study 32804250 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel grading systems for labral tear complexity, labral bruising, labral size, and extent of synovitis.
Number of subjects: 5
Study 32804250 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing classification systems for intra-articular lesions.
Number of subjects: 5
Study 32804250 — intervention group
Group type: EXPERIMENTAL
Intervention: Labral degeneration classification scheme.
Number of subjects: 5
Study 32980982 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block (CACB)
Number of subjects: 171
Study 32980982 — intervention group
Group type: COMPARATOR
Intervention: Adductor canal block (ACB)
Number of subjects: 171
Study 32980982 — intervention group
Group type: COMPARATOR
Intervention: Adductor canal block combined with IPACK
Number of subjects: 171
Study 32727706 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk (HR) nodal fields
Number of subjects: 216
Study 32727706 — intervention group
Group type: COMPARATOR
Intervention: Whole mediastinum (WM) fields
Number of subjects: 216
Study 32727706 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Number of subjects: 216
Study 33737661 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Random Noise Stimulation (tRNS)
Number of subjects: 27
Study 33737661 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 27
Study 33737661 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 27
Study 32027167 — intervention group
Group type: EXPERIMENTAL
Intervention: GP40061 insulin glargine (GP‐Gla)
Number of subjects: 180
Study 32027167 — intervention group
Group type: COMPARATOR
Intervention: Lantus® (Sanofi glargine, Sa‐Gla)
Number of subjects: 180
Study 35076629 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT and OCTA imaging in ERM group
Number of subjects: 276
Study 35076629 — intervention group
Group type: COMPARATOR
Intervention: Normal control eyes
Number of subjects: 276
Study 33660798 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (alone or in combination with chemotherapy)
Number of subjects: 11
Study 33660798 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 11
Study 33660798 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 11
Study 33660798 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 11
Study 33660798 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (control group)
Number of subjects: 11
Study 33660798 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab combined with chemotherapy
Number of subjects: 11
Study 33091038 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen avoidance strategy
Number of subjects: 0
Study 33091038 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone
Number of subjects: 0
Study 33091038 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35432822 — intervention group
Group type: EXPERIMENTAL
Intervention: 360° safe indwelling needle
Number of subjects: 1000
Study 35432822 — intervention group
Group type: COMPARATOR
Intervention: Routine indwelling needle
Number of subjects: 1000
Study 33725327 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose protocol stereoradiography
Number of subjects: 30
Study 33725327 — intervention group
Group type: COMPARATOR
Intervention: Standard low-dose protocol stereoradiography
Number of subjects: 30
Study 35443809 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced crystalloids
Number of subjects: 1157
Study 35443809 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 1157
Study 33838757 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 990
Study 33838757 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 990
Study 33838757 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 990
Study 35122746 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) for 6 weeks, 1 hour daily sessions
Number of subjects: 60
Study 35122746 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 60
Study 35122746 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 60
Study 33598835 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor air of PCCs with LaserJet printers
Number of subjects: 53
Study 33598835 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor air of PCCs with inkjet printers
Number of subjects: 53
Study 33598835 — intervention group
Group type: COMPARATOR
Intervention: Indoor air of PCCs (general)
Number of subjects: 53